[go: up one dir, main page]

EP1064022A4 - Hla-binding peptides and their uses - Google Patents

Hla-binding peptides and their uses

Info

Publication number
EP1064022A4
EP1064022A4 EP98910404A EP98910404A EP1064022A4 EP 1064022 A4 EP1064022 A4 EP 1064022A4 EP 98910404 A EP98910404 A EP 98910404A EP 98910404 A EP98910404 A EP 98910404A EP 1064022 A4 EP1064022 A4 EP 1064022A4
Authority
EP
European Patent Office
Prior art keywords
hla
binding peptides
peptides
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98910404A
Other languages
German (de)
French (fr)
Other versions
EP1064022A1 (en
Inventor
Alessandro Sette
Ralph T Kubo
John Sidney
Esteban Celis
Howard M Grey
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of EP1064022A1 publication Critical patent/EP1064022A1/en
Publication of EP1064022A4 publication Critical patent/EP1064022A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP98910404A 1998-03-13 1998-03-13 Hla-binding peptides and their uses Withdrawn EP1064022A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/005039 WO1999045954A1 (en) 1998-03-13 1998-03-13 Hla-binding peptides and their uses

Publications (2)

Publication Number Publication Date
EP1064022A1 EP1064022A1 (en) 2001-01-03
EP1064022A4 true EP1064022A4 (en) 2004-09-29

Family

ID=22266589

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98910404A Withdrawn EP1064022A4 (en) 1998-03-13 1998-03-13 Hla-binding peptides and their uses

Country Status (5)

Country Link
EP (1) EP1064022A4 (en)
JP (1) JP2002507397A (en)
AU (1) AU6465598A (en)
CA (1) CA2323632A1 (en)
WO (1) WO1999045954A1 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US6291430B1 (en) * 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
EP1117679B9 (en) 1998-10-02 2010-07-07 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
US6407063B1 (en) 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
US6541214B1 (en) * 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
GB9826143D0 (en) * 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
CA2353102A1 (en) * 1998-12-01 2000-06-08 Sumitomo Pharmaceuticals Company, Limited Novel tumor antigen protein art-1 and tumor antigen peptide thereof
IT1309584B1 (en) * 1999-02-26 2002-01-24 San Raffaele Centro Fond IMMUNOGENIC PEPTIDES DERIVED FROM MAGE-3 PRESENTED BY MHC OF CLASS II AND THEIR USE.
WO2001032193A1 (en) * 1999-10-29 2001-05-10 Argonex Pharmaceuticals Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma
JP4776131B2 (en) * 1999-11-18 2011-09-21 エピミューン インコーポレイテッド Heteroclitic analogs and related methods
EP1237564A4 (en) * 1999-12-10 2005-05-04 Epimmune Inc INDUCTION OF CELLULAR IMMUNE RESPONSES TO P53 BY PEPTIDE AND NUCLEIC ACID COMPOUNDS
JP2003530083A (en) * 1999-12-10 2003-10-14 エピミューン インコーポレイテッド Induction of a Cellular Immune Response to HER2 / neu Using Peptide and Nucleic Acid Compositions
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
JP2003517310A (en) * 1999-12-10 2003-05-27 エピミューン， インコーポレイテッド Induction of a cellular immune response against MAGE2 / 3 using peptide and nucleic acid compositions
JP2003521245A (en) * 1999-12-21 2003-07-15 エピミューン， インコーポレイテッド Inducing a Cellular Immune Response to Prostate Cancer Antigen Using Peptide and Nucleic Acid Compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
FR2806727A1 (en) * 2000-03-23 2001-09-28 Pf Medicament MOLECULE OF PHARMACEUTICAL INTEREST COMPRISING IN THE N-TERMINAL END A GLUTAMIC ACID OR GLUTAMINE IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE ACID ADDITION SALT
AU2001253029A1 (en) * 2000-03-30 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
CN1107681C (en) * 2000-08-11 2003-05-07 中国科学院微生物研究所 Compound of polypeptide as antigen of hepatitis B virus and heat shock protein and its application
CN1537164A (en) * 2000-08-14 2004-10-13 Compositions and methods for treating and diagnosing Her-2/neu-associated malignancies
WO2002020053A1 (en) * 2000-09-01 2002-03-14 Epimmune Inc. Hla binding peptides and their uses
EP1195381A1 (en) * 2000-09-28 2002-04-10 Immusystems GmbH Hepatitis c virus epitopes specific for cd4+ t-cell lymphocytes
US7241742B2 (en) 2000-10-31 2007-07-10 Mgi Pharma Biologics, Inc. CYP1B1 nucleic acids and methods of use
EP1490396A4 (en) * 2001-03-01 2006-04-19 Us Gov Health & Human Serv IMMUNOGENEOUS HIV PEPTIDES FOR USE AS REAGENTS AND VACCINES
EP2295074A1 (en) * 2001-03-07 2011-03-16 Mannkind Corporation Anti-neovasculature preparations for treating cancer
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
EP1752160A3 (en) * 2001-04-06 2007-05-30 Mannkind Corporation Epitope sequences
US20040202654A1 (en) 2001-04-09 2004-10-14 Mayo Foundation For Medical Education & Research Methods and materials for cancer treatment
WO2002094994A2 (en) 2001-05-18 2002-11-28 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
IL159202A0 (en) 2001-06-05 2004-06-01 Us Gov Health & Human Serv Peptides for chlamydophila pneumoniae vaccine and diagnosis
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
CA2357906A1 (en) 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
CA2469738A1 (en) 2001-11-07 2003-08-07 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
WO2003050140A1 (en) * 2001-12-10 2003-06-19 Kyogo Itoh Tumor antigens
WO2003087126A2 (en) * 2002-04-05 2003-10-23 Epimmune Inc. Heteroclitic analogs and related methods
DK1587837T3 (en) 2003-01-28 2012-09-24 Proscan Rx Pharma Inc Epitope sequences for the diagnosis and treatment of prostate cancer
WO2005007694A1 (en) * 2003-07-16 2005-01-27 Green Peptide Co., Ltd. HER2/neu PEPTIDE AND THERAPEUTIC USE TEHREOF
JP5097400B2 (en) * 2003-09-03 2012-12-12 デンドリセラピューティクス、インク． Combined vaccine
US7488793B2 (en) * 2003-09-22 2009-02-10 Ludwig Institute For Cancer Research Isolated peptide which binds to HLA-Cw*07 and uses thereof
KR100818578B1 (en) * 2003-09-22 2008-04-02 가부시키가이샤 그린 펩티드 Peptide originating in hepatitis c virus
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
WO2005103679A2 (en) 2004-04-21 2005-11-03 Algonomics Nv Method for affinity scoring of peptide/protein complexes
JP4761311B2 (en) * 2004-04-30 2011-08-31 日本電気株式会社 HLA-binding peptide, DNA fragment encoding it and recombinant vector
JP5176099B2 (en) * 2004-09-27 2013-04-03 国立大学法人 東京医科歯科大学 HLA-A11 restricted Tax anti-tumor epitope
JP5116150B2 (en) * 2005-09-07 2013-01-09 日本電気株式会社 HLA-binding peptide, DNA fragment encoding it and recombinant vector
WO2007120834A2 (en) 2006-04-13 2007-10-25 Peptimmune, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
WO2008010010A1 (en) * 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
NZ585367A (en) 2007-10-16 2012-12-21 Peptimmune Inc Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
BRPI0905729A2 (en) 2008-01-18 2015-07-14 Aeras Global Tb Vaccine Found "recombinant antigen polypeptide, recombinant antigen peptide, nucleic acid and method for immunizing an individual against malaria"
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
AU2010300623A1 (en) * 2009-09-30 2012-04-19 Saint Louis University Peptides for inducing heterosubtypic influenza T cell responses
EP2615104B1 (en) * 2010-09-08 2017-03-22 Saitama Medical University Hepatitis c virus liposome vaccine
DK3138581T3 (en) 2011-03-17 2019-04-15 Univ Birmingham REDIRECTED IMMUNTERY
CN102286075A (en) * 2011-08-01 2011-12-21 中国人民解放军第三军医大学 Hepatitis B virus surface antigen immunodominance HLA-A*1101 restricted cytotoxic T lymphocyte (CTL) epitope and use thereof
EP2753635A4 (en) 2011-09-09 2015-08-12 Agency Science Tech & Res PEPTIDES THAT ACTIVATE P53 PROTEIN
KR102047323B1 (en) * 2012-01-20 2019-11-21 페르난도 토메 크뤠츠 Autologous cancer cell vaccine
JP5999703B2 (en) * 2013-01-09 2016-09-28 国立大学法人 東京医科歯科大学 HLA-DR1-restricted Tax-specific CD4 + T cell epitope
SG11201706667XA (en) * 2015-02-18 2017-09-28 Hoffmann La Roche Immunoconjugates for specific induction of t cell cytotoxicity against a target cell
CN105037559B (en) * 2015-08-17 2018-09-25 北京康爱瑞浩生物科技股份有限公司 Treat or prevent the cytotoxic T lymphocyte and preparation method thereof of hepatitis B
CN109734777B (en) 2015-08-28 2023-04-07 伊玛提克斯生物技术有限公司 Novel peptides, peptide compositions and scaffolds for immunotherapy of various cancers
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
JP2020515283A (en) 2016-12-28 2020-05-28 インブバックス，インコーポレーテッド Influenza vaccine
KR102794702B1 (en) * 2017-09-01 2025-04-11 다나-파버 캔서 인스티튜트 인크. Immunogenic peptides specific for BCMA and TACI antigens for the treatment of cancer
EP3545967A1 (en) * 2018-03-28 2019-10-02 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Cancer immunization platform
US12247053B2 (en) 2018-10-26 2025-03-11 Saint Louis University Peptides for inducing heterosubtypic influenza T cell responses
EP3908591A4 (en) * 2019-01-11 2023-01-25 Agency for Science, Technology and Research USE OF HLA-A*11:01 RESTRICTED HEPATITIS B VIRUS (HBV) PEPTIDES TO IDENTIFY HBV-SPECIFIC CD8+ T-LYMPHOCYTES
CA3132435A1 (en) * 2019-03-04 2020-09-10 University Health Network T cell receptors and methods of use thereof
CN111116719B (en) * 2019-12-13 2022-12-13 南京大户生物科技有限公司 Thymus dependent lymphocyte antigen epitope peptide of hepatitis B virus antigen and its application

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
WO1997033602A1 (en) * 1996-03-11 1997-09-18 Cytel Corporation Peptides with increased binding affinity for hla molecules
WO1997034617A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla binding peptides and their uses
WO1997034621A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla-a2.1 binding peptides and their uses
WO1998032456A1 (en) * 1997-01-23 1998-07-30 Epimmune, Inc. Identification of broadly reactive dr restricted epitopes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
WO1997033602A1 (en) * 1996-03-11 1997-09-18 Cytel Corporation Peptides with increased binding affinity for hla molecules
WO1997034617A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla binding peptides and their uses
WO1997034621A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla-a2.1 binding peptides and their uses
WO1998032456A1 (en) * 1997-01-23 1998-07-30 Epimmune, Inc. Identification of broadly reactive dr restricted epitopes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALTUVIA YAEL ET AL: "A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets", HUMAN IMMUNOLOGY, vol. 58, no. 1, November 1997 (1997-11-01), pages 1 - 11, XP002279422, ISSN: 0198-8859 *
GREY H M ET AL: "CLASS I MHC-PEPTIDE INTERACTIONS: STRUCTURAL REQUIREMENTS AND FUNCTIONAL IMPLICATIONS", CANCER SURVEYS, OXFORD, GB, vol. 22, 1995, pages 37 - 49, XP008024840 *
PARTIDOS C D ET AL: "Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides", IMMUNOLOGY, vol. 87, no. 2, 1996, pages 179 - 185, XP002279421, ISSN: 0019-2805 *
See also references of WO9945954A1 *

Also Published As

Publication number Publication date
EP1064022A1 (en) 2001-01-03
AU6465598A (en) 1999-09-27
CA2323632A1 (en) 1999-09-16
WO1999045954A1 (en) 1999-09-16
JP2002507397A (en) 2002-03-12

Similar Documents

Publication Publication Date Title
EP1064022A4 (en) Hla-binding peptides and their uses
HUP0102535A3 (en) Cd19xcd3 specific polypeptides and uses thereof
PL346346A1 (en) Cyclic prosaposin-derived peptides and uses thereof
IL128869A0 (en) Pyrozolopyrimidines and pyrazolotriazines
IL131368A0 (en) Antipathogenic synthetic peptides and compositions comprising them
GB9806806D0 (en) Peptides and uses thereof
ZA97283B (en) Isolated tyrosinase derived peptides and uses thereof
IL131707A0 (en) Acetylcholinesterase-derived peptides and uses thereof
GB9718110D0 (en) Peptides
GB9825854D0 (en) Peptide
GB0127669D0 (en) Polypeptide
GB9700154D0 (en) Peptides
GB9918155D0 (en) Proteins and peptides
GB9714276D0 (en) Peptides and related compounds
GB9812675D0 (en) Peptides
EP1080185A4 (en) Myelin basic protein peptides and uses thereof
IL145711A0 (en) Thrombospondin-2 and uses thereof
GB9917165D0 (en) Polypeptides polynuclcotides and uses thereof
PL341293A1 (en) Beta-lypothropin and application thereof
GB9807890D0 (en) Peptides
EP1132472A4 (en) Novel protein and utilization thereof
GB9828036D0 (en) Oligopeptides and their use
GB9800321D0 (en) Peptides
GB9818368D0 (en) Vitronectin-derived peptides
GB9827603D0 (en) Peptides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000929

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EPIMMUNE INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/82 B

Ipc: 7C 07K 14/02 B

Ipc: 7C 07K 7/00 B

Ipc: 7A 61K 39/00 B

Ipc: 7A 61K 39/29 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040813

17Q First examination report despatched

Effective date: 20070820

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080401